NEW YORK (GenomeWeb) – IBM Watson Health announced today that it has signed an agreement making Baheal Pharmaceutical Group the primary channel partner for its Watson for Genomics platform in China.

Watson for Genomics is designed to analyze large sets of genomic, clinical, and pharmacological data to generate a report for physicians that identifies genetic alterations that are actionable based on literature, as well as drugs and clinical trials that target those alterations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.